Abstract
PurposeThe aim of the current study is to evaluate the effect of age as an independent factor for the response to two anti-VEGF agents, intravitreal ranibizumab and intravitreal aflibercept, among patients presented with central-involving DME in one tertiary care center in Riyadh, Saudi Arabia. MethodsRetrospective cohort study. ResultsA total of 210 eyes of 121 patients were included in the study. The mean age was 61.2 & PLUSMN; 11.40 years, 50.4% were males. On characterizing groups based on age, the group of patients 60 years or younger are 48 patients (mean age 51.5 & PLUSMN; 9.92) and 52.1% of them are females. On the other hand, the group of patients older than 60 years are 73 patients (mean age 67.6 & PLUSMN; 6.85) and 52.1% of them are males. The two anti-VEGF agents used were aflibercept (88.1%) and ranibizumab (11.9%). The mean BCVA using ETDRS letter score improved after treatment (5.55238095 & PLUSMN; 15.9538695) and the mean change in CST decreased after treatment (- 106.91 & PLUSMN; 117.385 mu m). Regarding age, we found that there is no significant difference in mean improvement of BCVA in patients according to their age (p = 0.5429), patients younger than 60 years old gained 5.64 ETDRS letter score and those older than 60 years old gained 5.49 improvement. Similarly, mean improvement in CST was different between patients younger than 60 years old (- 125.1 mu m) and those who were older than 60 years old (- 94 mu m) with a trend favoring younger patients but this difference was not statistically significant (p = 0.08). ConclusionAge is a clinically significant factor affecting the outcome of anti-VEGF injections. Patients' CST had a difference of > 30 mu m on average between the two age groups favoring younger patients. However, it was not statistically significant, maybe a bigger sample size is needed to prove statistical significance.